A Study to Evaluate the Effects of ABX-1431 on Patients With Tourette Syndrome

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

October 4, 2017

Study Completion Date

October 4, 2017

Conditions

Tourette SyndromeChronic Motor Tic Disorder

Interventions

DRUG

ABX-1431

ABX-1431, capsules, 40 mg in the fasting state

DRUG

Placebo Comparator

Matching Placebo

DRUG

ABX-1431

ABX-1431, capsules, 20 mg with a high fat meal

Trial Locations (1)

Medizinische Hochschule Hannover, Hanover